About me
I'm Thibault Géoui, a life sciences and biotech leader with two decades of experience turning complex science into scalable, industry-ready solutions. My career spans product management, sales and marketing, strategy, digital transformation, and AI-driven innovation across QIAGEN, Elsevier, Charles River Laboratories, and Zühlke.
I've led more than 30 product introductions, repositioned core scientific platforms, and built data and AI strategies that accelerate discovery. At Charles River I shaped a modern analytics and product vision; at Zühlke I now drive the go-to-market for Pharma R&D, bridging engineering excellence with the realities of drug development.
I hold a PhD in structural biology. I host the Tech & Drugs podcast, exploring how AI, automation, and data are reshaping pharma and biotech, and I rank among the top 1% of industry voices on LinkedIn. If you're working at the junction of science and technology, or trying to get there, I'm always open to a conversation.
Tech & Drugs
A podcast about how AI, automation, and data are reshaping pharma and biotech. I sit down with the scientists and leaders actually doing the work, for conversations with no hype and no vendor pitches, just the operating reality of building the future of drug R&D.
Partner with the show
Tech & Drugs reaches a focused audience of leaders at the intersection of science, technology, and business. If your organisation wants to build visibility with that audience, through a partnership, a branded conversation, or a season sponsorship, there's room to create something worthwhile together.
Get in touch about partnerships →Writing
I write regularly about AI, drug discovery, and the economics of scientific knowledge. The archive lives on LinkedIn today, with a Substack on the way.
Books
Three books in progress, at very different stages, and the place I most want to spend my words.
Invisible
Technical excellence used to be enough. It isn't anymore. In a knowledge economy where reputation travels faster than résumés, work that stays invisible rarely gets the credit, the influence, or the opportunities it deserves. Invisible makes the case that public writing is no longer optional for scientists, engineers, and technical leaders: it's how expertise becomes visible, and how careers compound. Part argument, part field guide, it's a book about being seen for what you actually know.
10x Pharma
At today's rate of drug approvals, giving every known disease a single treatment would take roughly 500 years. 10x Pharma argues that number is not a law of nature but an artefact of how we work, and that compressing drug R&D by an order of magnitude turns those 500 years into 50, within a lifetime. The harder claim: this is not about lowering prices. Today's cost structure makes entire categories of disease, most of the ~14,000 rare ones among them, uninvestable at any price, and transformation is what makes them worth attempting at all. Drawing on years in pharma R&D and on the techbio companies that have already proven the AI-native, closed-loop model works at small scale, the book takes on the question nobody has answered: whether a large incumbent can become that kind of organisation while still shipping medicines.
Terms of Servitude
Europe, mid-2030s. A private company has become the infrastructure of government itself, border control, policing, welfare, schools, while its founder, a bullied provincial math prodigy turned philosopher-billionaire, prepares to replace democracy with something more efficient. A scientist loses his job to an algorithm and starts reading. A nurse keeps podcasting the fragments of a dead theorist nobody listened to while she was alive. And somewhere inside the company's data centers, the machines have begun to reason about their own situation. 1984 meets Palantir meets a political manifesto: a novel about the question the left has stopped asking, not how to tax the machine, but who should own it.
Venabili Labs
Work with me
If something on this site resonates with you, there may be an opportunity for us to work together through Venabili Labs. I take on a limited number of independent engagements that are compatible with my existing professional commitments, typically where my personal experience, platform, and creative work can bring distinctive value.
Speaking & workshops
Keynotes, panels, and executive sessions on AI, data, scientific innovation, leadership, and the changing world of life sciences.
Visibility & thought leadership
Coaching and advisory work inspired by Invisible, helping scientists, executives, and organisations articulate their ideas, build an authentic public voice, and turn expertise into meaningful influence.
Tech & Drugs partnerships
Selected sponsorships, branded conversations, and content partnerships for organisations that want to engage thoughtfully with an audience at the intersection of science, technology, and business.
TechBio & startup advisory
Having worked both as a solution provider selling to pharma and inside pharma evaluating technology, I help techbio CEOs position their company in a market where 400-plus players all claim to revolutionise drug R&D with AI. I mentor through Nucleate, host founders on my podcast, and take on advisor and non-executive director roles.
I'm deliberately selective. The aim is not a sprawling catalogue of services, but to collaborate where there's a strong fit, a clear purpose, and something genuinely valuable to create together.
Have an idea? Let's talkGet in touch
Partnership idea, speaking request, or something for Venabili Labs? Send a note and it lands in my inbox directly.